1AD.AX
ADALTA FPO [1AD]
A$0.00
+12.50%
2026-05-29
About ADALTA FPO [1AD]
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe University. The company was incorporated in 2006 and is based in Camberwell, Australia.
Key Fundamentals
Forward P/E
-0.15
EPS (TTM)
A$0.00
Revenue Growth (YoY)
-18.4%
Profit Margin
0.0%
Beta
0.20
Market Cap
A$11.5M
Avg Volume (10D)
3.3M
Recent Breakout Signals
No recent breakout signals detected for 1AD.AX.
Recent Price Range (60 Days)
60D High
A$0.01
60D Low
A$0.00
Avg Volume
4.6M
Latest Close
A$0.00
Get breakout alerts for 1AD.AX
Sign up for Breakout Scanner to receive daily notifications when 1AD.AX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
ADALTA FPO [1AD] (1AD.AX) is listed on the Australian Securities Exchange (ASX). Breakout Scanner monitors 1AD.AX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 1AD.AX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.